• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Canada·Healthcare·CLABF
Share

Core One Labs Inc. Stocks

$ 0Last Updated 26.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 471

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Core One Labs Inc. operates as a psychedelic research and development company. The company focuses on providing psychedelic medicines to novel delivery systems and psychedelic assisted psychotherapy; and intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. It also provides natural health products; news dissemination services; financing services; and operates medical clinics, as well as engages in micro cultivation. The company was formerly known as Lifestyle Delivery Systems Inc. and changed its name to Core One Labs Inc. in September 2019. Core One Labs Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.

Company Valuation

Slightly overvalued
3/7

Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.10.2026 01:34

Microsoft Beat Forecasts for Cloud Revenue

29.10.2026 01:17

"The Moment of Truth": Alphabet Shares Plunge 10% After Disappointing Earnings Report

29.10.2026 01:07

The U.S. Federal Reserve will reduce the number of interest rate meetings starting in 2027

29.10.2026 00:35

Is this the end of the “Magnificent Seven”? Big Tech stocks have diverged in their performance. Which ones should you choose?

29.10.2026 00:10

Oracle surprised the market with its cash flow forecast. Its shares soared 12%.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026